Titre :
  • A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Auteur : Green, M D ; Koelbl, H ; Baselga, J ; Galid, A ; Guillem, V ; Gascon, P ; Siena, S ; Lalisang, R I ; Samonigg, H ; Clemens, Michael ; Zani, V ; Liang, B C ; Renwick, Jennifer ; Piccart-Gebhart, Martine ; International Pegfilgrastim 749 Study Group
Informations sur la publication : Annals of oncology, 14, 1, (page 29-35)
Statut de publication : Publié, 2003-01
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Delayed-Action Preparations
Double-Blind Method
Doxorubicin -- administration & dosage
Doxorubicin -- adverse effects
Drug Administration Schedule
Female
Filgrastim -- administration & dosage
Filgrastim -- analogs & derivatives
Humans
Middle Aged
Neoplasm Staging
Neutropenia -- chemically induced
Neutropenia -- drug therapy
Neutrophils -- physiology
Paclitaxel -- administration & dosage
Paclitaxel -- adverse effects
Paclitaxel -- analogs & derivatives
Taxoids
Note : Clinical Trial
Clinical Trial, Phase III
Comment
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0923-7534 
info:pmid/12488289